MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Matinas BioPharma Holdings Operating Expenses 2011-2026 | MTNB
Annual Operating Expenses Matinas BioPharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 24.4 M | 19 M | 14.8 M | 16.7 M | 8.26 M | 10.1 M | 10.5 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.4 M | 8.26 M | 14.8 M |
Quarterly Operating Expenses Matinas BioPharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.45 M | 4.02 M | 4.5 M | - | 1.84 M | 1.62 M | 2.24 M | - | 2.22 M | 2.48 M | 2.63 M | - | 2.61 M | 2.42 M | 2.13 M | - | 1.45 M | 343 K | 112 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.5 M | 112 K | 2.27 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 0.77 | -4.12 % | $ 35.2 M |  Israel |
 |
Exelixis
EXEL
|
598 M | $ 48.16 | 4.22 % | $ 13.1 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 94.13 | 1.19 % | $ 22.8 B | Germany |
 |
Fortress Biotech
FBIO
|
125 M | $ 2.39 | -0.42 % | $ 66.7 M | USA |
|
Forte Biosciences
FBRX
|
70.7 M | $ 24.02 | -8.22 % | $ 311 M | USA |
 |
Compugen Ltd.
CGEN
|
40.4 M | $ 2.9 | 1.4 % | $ 271 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.4 | -0.71 % | $ 3.71 B | USA |
 |
Genmab A/S
GMAB
|
67.9 M | $ 26.43 | -2.33 % | $ 1.71 B |  Danmark |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 3.14 | - | $ 653 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.51 | -0.85 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
Gilead Sciences
GILD
|
13.5 B | $ 131.33 | -2.04 % | $ 163 B | USA |
 |
Genprex
GNPX
|
18 M | $ 0.87 | 0.58 % | $ 811 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.17 | 2.47 % | $ 2.69 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 8.1 | 0.5 % | $ 5.51 B |  Spain |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 54.83 | 4.6 % | $ 4.93 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.57 | -2.48 % | $ 418 M | Britain |